India-based Glenmark Pharmaceuticals (NSE: GLENMARK) has been granted final approval by the US health regulator to market its generic version of Rythmol SR capsules, the company confirmed on Monday.
Rythmol SR capsules are indicated as an anti-arrhythmic medication, used in the treatment of illnesses whose symptoms include rapid heartbeats.
The US Food and Drug Administration (FDA) granted its approval for Propafenone Hydrochloride extended-release capsules USP, 225 mg, 325 mg and 425 mg.
Rythmol SR is a product of GlaxoSmithKline LLC.
The approval marks the company's 123rd product to gain approval for commercialisation in the US marketplace. It also has 63 Abbreviated New Drug Applications (ANDA) currently pending approval with the FDA.
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
Agilent launches S540MD slide scanner system in US
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA